Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment

NCT02822573 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT02822573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02822573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 3
Overall status
Completed
Start date
May 30, 2017
Completion date
July 29, 2022
Enrollment
276 (actual)
Sites
278

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive dysfunction, memory impairment